trending Market Intelligence /marketintelligence/en/news-insights/trending/hTpa11FBCU91BTKZUjgRww2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cellectar Biosciences closes $7.8M registered direct offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Cellectar Biosciences closes $7.8M registered direct offering

Cellectar Biosciences Inc. closed a registered direct offering of 1,954,388 common shares and 41.0412949 preferred shares.

The preferred stock was offered at $100,000 per share and is immediately convertible into about 53,369 shares for a total of 2,190,330 shares upon conversion at a price of $1.87375 per share.

The company received gross proceeds of about $7.8 million.

Cellectar Biosciences also offered the purchasers series D warrants to buy an aggregate of 3,108,538 common shares as part of a concurrent private placement.

The warrants have an exercise price of $1.78, will be immediately exercisable and will expire in 7 years.

Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent in connection with the offering.